Email this article Analytical aspects of gastrin measurement in neuroendocrine tumors
- Authors: Lyubimova N.V.1, Churikova T.K.1, Timofeev Y.S.1, Kharitidy T.Y.1, Kushlinskii N.E.1
-
Affiliations:
- N.N. Blokhin National Medical Research Centre of Oncology
- Issue: Vol 46, No 3 (2018)
- Pages: 264-269
- Section: ARTICLES
- URL: https://almclinmed.ru/jour/article/view/828
- DOI: https://doi.org/10.18786/2072-0505-2018-46-3-264-269
- ID: 828
Cite item
Full Text
Abstract
Rationale: Biochemical diagnostics of neuroendocrine tumors (NETs) is based on the analysis of universal and specific markers, according to the tumor type and clinical manifestations of the disease. Measurement of gastrin levels in the serum of NETs patients is important in the diagnosis of the functioning pancreatic, gastric and duodenal NETs.
Aim: To perform a comparative analysis of the results of gastrin measurement as a biochemical marker of NETs using different test-systems.
Materials and methods: Serum gastrin was measured in the serum of 30 NET patients and 18 normal controls by immunochemiluminescent (Immulite 2000 Gastrin, “Siemens”) and ELISA (Gastrin-17 ELISA, “Biohit”) assays.
Results: The analysis of the results of gastrin measurement by immunochemiluminescent and ELISA methods showed significant variability of its levels, reaching 2016 and 1988 pmol/l, respectively. Comparable analytical sensitivity of the two test systems was confirmed by similar increases (over 30- to 40-fold) of the median levels of the hormone in the serum of patients with gastric NETs, compared to healthy controls. The analysis of diagnostic efficacy accounting for their respective cut-offs demonstrated higher sensitivity (95.4%) of the Immulite 2000 Gastrin test-system, which measures total gastrin, than that of the ELISA method (80.0%), specific to gastrin-17.
Conclusion: The analysis shows high efficacy of immonochemiluminescent method of measurement of total gastrin as a biochemical marker of NETs.
Keywords
About the authors
N. V. Lyubimova
N.N. Blokhin National Medical Research Centre of Oncology
Author for correspondence.
Email: biochimia@yandex.ru
Nina V. Lyubimova – Doctor of Biol. Sci., Professor, Leading Research Fellow, Laboratory of Clinical Biochemistry.
24 Kashirskoe shosse, Moscow, 115478, tel.: +7 (499) 324 11 69
Russian FederationT. K. Churikova
N.N. Blokhin National Medical Research Centre of Oncology
Email: fake@neicon.ru
Tatiana K. Churikova – Physician, Laboratory of Clinical Biochemistry.
24 Kashirskoe shosse, Moscow, 115478
Russian FederationYu. S. Timofeev
N.N. Blokhin National Medical Research Centre of Oncology
Email: fake@neicon.ru
Yuriy S. Timofeev – PhD, Physician, Laboratory of Clinical Biochemistry.
24 Kashirskoe shosse, Moscow, 115478
Russian FederationT. Yu. Kharitidy
N.N. Blokhin National Medical Research Centre of Oncology
Email: fake@neicon.ru
Tatiana Yu. Kharitidy – PhD (in Biology), Senior Research Fellow, Laboratory of Clinical Biochemistry.
24 Kashirskoe shosse, Moscow, 115478
Russian FederationN. E. Kushlinskii
N.N. Blokhin National Medical Research Centre of Oncology
Email: fake@neicon.ru
Nikolay E. Kushlinskii – MD, PhD, Professor, Member-Correspondent of Russian Academy of Sciences, Head of Laboratory of Clinical Biochemistry.
24 Kashirskoe shosse, Moscow, 115478
Russian FederationReferences
- Ardill JE. Circulating markers for endocrine tumours of the gastroenteropancreatic tract. Ann Clin Biochem. 2008;45(Pt 6): 539–59. doi: 10.1258/acb.2008.008039.
- Modlin IM, Latich I, Zikusoka M, Kidd M, Eick G, Chan AK. Gastrointestinal carcinoids: the evolution of diagnostic strategies. J Clin Gastroenterol. 2006;40(7): 572–82.
- Vinik AI, Silva MP, Woltering EA, Go VL, Warner R, Caplin M. Biochemical testing for neuroendocrine tumors. Pancreas. 2009;38(8): 876– 89. doi: 10.1097/MPA.0b013e3181bc0e77.
- Aluri V, Dillon JS. Biochemical testing in neuroendocrine tumors. Endocrinol Metab Clin North Am. 2017;46(3): 669–77. doi: 10.1016/j.ecl.2017.04.004.
- Любимова НВ, Чурикова ТК, Кушлинский НЕ. Хромогранин А – биохимический маркер нейроэндокринных опухолей. Бюллетень экспериментальной биологии и медицины. 2015;16(11): 657–60.
- Rehfeld JF, Bardram L, Hilsted L, Poitras P, Goetze JP. Pitfalls in diagnostic gastrin measurements. Clin Chem. 2012;58(5): 831–6. doi: 10.1373/clinchem.2011.179929.
- Burkitt MD, Varro A, Pritchard DM. Importance of gastrin in the pathogenesis and treatment of gastric tumors. World J Gastroenterol. 2009;15(1): 1–16. doi: 10.3748/wjg.15.1.
- Eastvold ML, Wallinder HW, Preissner CM, Singh RJ, Löwbeer C, Grebe SK. A two-center international evaluation of the Immulite 2000 automated serum gastrin assay. Clin Biochem. 2006;39(4): 387–90. doi: 10.1016/j.clinbiochem.2006.01.004.
- Rehfeld JF, Gingras MH, Bardram L, Hilsted L, Goetze JP, Poitras P. The Zollinger-Ellison syndrome and mismeasurement of gastrin. Gastroenterology. 2011;140(5): 1444–53. doi: 10.1053/j.gastro.2011.01.051.
- Oberg K, Couvelard A, Delle Fave G, Gross D, Grossman A, Jensen RT, Pape UF, Perren A, Rindi G, Ruszniewski P, Scoazec JY, Welin S, Wiedenmann B, Ferone D; Antibes Consensus Conference participants. ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Biochemical Markers. Neuroendocrinology. 2017;105(3): 201–11. doi: 10.1159/000472254.
Supplementary files
